Product Information
LETROZOLE 2.5 MG TABLET is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.1450 per EA under NDC 00093762056. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jun 3, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2.5 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093762056
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LETROZOLEApproval Type
Generic (ANDA)
FDA Application
ANDA090289FDA Approved
6/3/2011
TE Code
AB
On Market Since
6/3/2011
Pharmacological Classes
Price Statistics
The NADAC for LETROZOLE 2.5 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 17.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1450 per EA |
|---|---|
| All-time high | $0.1962 (Feb 12, 2014) |
| All-time low | $0.1009 (Jun 21, 2023) |
| 52-week high | $0.1535 |
| 52-week low | $0.1292 |
| Median price | $0.1424 |
| Average price | $0.1455 |
| Largest weekly change | +32.3% (Nov 22, 2023) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Letrozole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LETROZOLE 2.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LETROZOLE 2.5 MG TABLET, manufactured by Teva Pharmaceuticals USA Inc., is $0.1450 per EA (NDC 00093762056), effective Sep 30, 2026.
How has the price of LETROZOLE 2.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for LETROZOLE 2.5 MG TABLET has declined 17.6%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for LETROZOLE 2.5 MG TABLET?
Since Nov 28, 2013, the NADAC for LETROZOLE 2.5 MG TABLET has ranged from a low of $0.1009 (Jun 21, 2023) to a high of $0.1962 (Feb 12, 2014), with a median of $0.1424 per EA.
Are there cheaper alternatives to LETROZOLE 2.5 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LETROZOLE 2.5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures LETROZOLE 2.5 MG TABLET?
LETROZOLE 2.5 MG TABLET (NDC 00093762056) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.